VIVEK SUBBIAH to Administration, Intravenous
This is a "connection" page, showing publications VIVEK SUBBIAH has written about Administration, Intravenous.
Connection Strength
0.210
-
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncol. 2020 05; 21(5):645-654.
Score: 0.169
-
Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma. J Immunother Cancer. 2019 09 18; 7(1):253.
Score: 0.041